Carolyn R. Bertozzi's most recent trade in OmniAb Inc was a trade of 40,000 Stock Option (right to buy) done . Disclosure was reported to the exchange on June 17, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| OmniAb Inc | Carolyn R. Bertozzi | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2025 | 40,000 | 40,000 | - | - | Stock Option (right to buy) | |
| OmniAb Inc | Carolyn R. Bertozzi | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Jun 2025 | 20,000 | 17,769 | - | - | Restricted Stock Units | |
| OmniAb Inc | Carolyn R. Bertozzi | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2025 | 20,000 | 37,769 | - | - | Restricted Stock Units | |
| OmniAb Inc | Carolyn R. Bertozzi | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Jun 2025 | 20,000 | 75,539 | - | - | Common Stock | |
| Alnylam Pharmaceuticals Inc | Carolyn R. Bertozzi | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 May 2025 | 1,558 | 1,558 | - | - | Stock Option (right to buy) | |
| Alnylam Pharmaceuticals Inc | Carolyn R. Bertozzi | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 May 2025 | 775 | 775 (0%) | 0% | 0 | Common Stock | |
| OmniAb Inc | Carolyn R. Bertozzi | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Nov 2024 | 17,769 | 55,539 | - | - | Common Stock | |
| OmniAb Inc | Carolyn R. Bertozzi | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Nov 2024 | 17,769 | 37,769 | - | - | Restricted Stock Units | |
| OmniAb Inc | Carolyn R. Bertozzi | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jun 2024 | 40,000 | 40,000 | - | - | Stock Option (right to buy) | |
| OmniAb Inc | Carolyn R. Bertozzi | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Jun 2024 | 20,000 | 37,770 | - | - | Common Stock | |
| OmniAb Inc | Carolyn R. Bertozzi | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Jun 2024 | 20,000 | 35,538 | - | - | Restricted Stock Units | |
| OmniAb Inc | Carolyn R. Bertozzi | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jun 2024 | 20,000 | 55,538 | - | - | Restricted Stock Units | |
| Alnylam Pharmaceuticals Inc | Carolyn R. Bertozzi | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 May 2024 | 5,228 | 5,228 | - | - | Stock Option (right to buy) | |
| OmniAb Inc | Carolyn R. Bertozzi | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jun 2023 | 40,000 | 40,000 | - | - | Stock Option (right to buy) | |
| OmniAb Inc | Carolyn R. Bertozzi | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jun 2023 | 20,000 | 73,308 | - | - | Restricted Stock Units | |
| Alnylam Pharmaceuticals Inc | Carolyn R. Bertozzi | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jan 2023 | 4,268 | 4,268 | - | - | Stock Option (right to buy) | |
| Eli Lilly | Carolyn R. Bertozzi | Director | Grant, award, or other acquisition of securities at price $ 140.59 per share. | 16 Nov 2020 | 1,245 | 6,243 (0%) | 0% | 140.6 | 175,035 | Common Stock |